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a  b  s  t  r  a  c  t
Infectious  disease  models  are both  concise  statements  of hypotheses  and  powerful  techniques  for  creating
tools  from  hypotheses  and  theories.  As  such,  they  have  tremendous  potential  for guiding data  collection  in
experimental  and  observational  studies,  leading  to more  efﬁcient  testing  of  hypotheses  and  more  robust
study  designs.  In numerous  instances,  infectious  disease  models  have  played  a key  role in  informing  data
collection,  including  the Garki  project  studying  malaria,  the  response  to  the  2009  pandemic  of  H1N1
inﬂuenza  in the  United  Kingdom  and  studies  of  T-cell  immunodynamics  in  mammals.  However,  such
synergies  remain  the exception  rather  than  the rule;  and  a close  marriage  of  dynamic  modeling  and
empirical  data  collection  is  far  from  the  norm  in  infectious  disease  research.  Overcoming  the challenges
to  using  models  to  inform  data  collection  has  the  potential  to accelerate  innovation  and  to  improve
practice  in  how  we deal  with  infectious  disease  threats.
©  2014  The  Authors.  Published  by Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction: What is the role of models in data collection?
When people refer to “models” of infectious disease transmis-
sion, they usually mean something far more speciﬁc than the word
“model” indicates. The term is generally used to refer to a system
of equations or computer program that explicitly represents the
mechanisms of disease transmission and pathogenesis. This is in
contrast to models purely of statistical association that are common
throughout the medical literature. By setting forth a mechanis-
tic hypothesis in a mathematically precise form, models become
tools for generating (perhaps unexpected) predictions which can be
used to test the underlying hypotheses through confrontation with
data. Though this use of models has a long tradition throughout all
branches of science (including infectious disease epidemiology and
ecology), it often takes a back seat to other uses of infectious dis-
ease models. The highest proﬁle infectious disease modeling work
∗ Corresponding author. Tel.: +1 410 955 3551.
E-mail address: justin@jhu.edu (J. Lessler).
is often aimed at making predictions or ﬁlling in gaps in existing
data. These uses of models by deﬁnition presume that the hypoth-
esis captured in the model is close enough to the truth to capture the
dynamics of the system relevant to the task at hand, and provide
answers only conditional on the correctness of the model. While
many researchers put great effort into ﬁtting both the structure and
parameters of models using existing data, data are rarely collected
with the explicit purpose of testing model hypotheses, and many
models go unchallenged and untested after they are ﬁrst presented.
Models are powerful, in part, because they can turn a hypoth-
esis or theory into a tool for making precise predictions. Yet even
in this capacity infectious disease models are underutilized in the
data collection process. For example, sample size calculations and
power analyses are de rigueur for the design of observational stud-
ies and clinical trials. However, cases of transmissible infections
are non-independent, limiting the utility of standard theory. Using
mechanistic models that account for the transmission process can
allow robust estimation in the setting of these “dependent hap-
penings” and tell us not only how much data to collect but when to
collect it (Halloran et al., 2010).
http://dx.doi.org/10.1016/j.epidem.2014.12.002
1755-4365/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Model-driven data collection does occur, and a prime exam-
ple is the Garki project (Molineaux et al., 1980). This seminal
project studied the transmission of malaria under different con-
trol interventions and captured longitudinal data on both disease
and vector dynamics. Thirty years after its publication it remains
one of the most valuable datasets for parameterizing malaria mod-
els (e.g., Grifﬁn et al., 2010), and has been cited over 650 times.
In part because input from models was used in the design of the
study, it provides an almost unique dataset on the dynamics of
malaria across a number of seasons and under different interven-
tions, providing an example for future studies which has rarely been
emulated.
Through sensitivity analysis and quantiﬁcation of uncertainty,
models can be used to elucidate the parameters and processes
that contribute most to our inability to make predictions with a
high degree of conﬁdence, and those which are less important.
They can thereby indicate where experimental effort would be best
directed to improve the predictive power of a model. An example of
where this is being attempted is HPTN 071 (PopART), a community
randomized trial of combination prevention packages including
early antiretroviral therapy initiation to control HIV transmission in
Africa. In the analysis of this trial, models are being used to estimate
endpoints (e.g., community incidence), improve study design, and
identify which processes are the main drivers of uncertainty (Cori
et al., 2014).
For the modeling of infectious disease to reach its full potential,
it must become more tightly integrated with the data collection
process. Despite successes such as those described above, signiﬁ-
cant challenges to successful model-driven data collection remain.
Some stem from technical or cultural issues that are, in principle,
easily surmountable. However, others are inherent in the role that
models are often called on to play in public health response and sci-
entiﬁc research, hence may  be difﬁcult or impossible to overcome.
In this paper, we start by discussing some fundamental chal-
lenges in the relationship between models and data collection, and
end with speciﬁc challenges in current practice. Throughout we
highlight the potential role of “modelers” in the data collection pro-
cess. Though infectious disease modeling has grown into a distinct
specialty, here we refer to anyone who deﬁnes and implements a
mechanistic model of disease transmission as a “modeler”. In addi-
tion to our headline challenges, we have tried to identify speciﬁc
research avenues under each (mentioned at the end of key para-
graphs) that could result in signiﬁcant progress in confronting the
challenge.
1. Ensuring a strong empirical basis for models used to ﬁll
gaps in data and knowledge
One primary role of models is to use our mechanistic under-
standing of a system to ﬁll gaps in available data. Gaps in knowledge
may  occur because data is difﬁcult or expensive to collect, because
we are trying to understand past events which can no longer be
directly observed, or because we are confronting a novel disease
which is not yet well understood. In each of these contexts models
play a hugely important role because of the lack of information, but
are at the same time hamstrung by the lack of data with which to
test model assumptions or ﬁt parameters. While data will always
be scarce in these situations, each presents an opportunity to use
mechanistic models to make more effective use of existing data and
guide ongoing data collection.
Data on disease incidence is difﬁcult and expensive to collect on
a broad scale; and passive clinical surveillance may  include only the
most severe cases or be clouded by a non-speciﬁc clinical proﬁle.
However, the burden of disease is one of the most fundamen-
tal pieces of epidemiologic information used in setting the public
health agenda. Hence, mechanistic models are often used to ﬁll
the gap. For instance, transmission models have been used to help
estimate the global burden of measles (Simons et al., 2012), using
our knowledge of how susceptibility drives epidemic dynamics to
infer the true number of cases from what was observed. Likewise,
models have been used to help translate observed cases of acute
ﬂaccid paralysis to polio incidence through our understanding of
transmission and the symptomatic attack rate (Eichner and Dietz,
1996). There are opportunities to test and improve models that
ﬁll data gaps. Models can be used to identify efﬁcient data col-
lection activities that validate the model but do not require the
effort and expense of collecting the data the model is meant to
infer. Innovative methods and systems for updating both the model
predictions and the model assumptions in real time as new surveil-
lance data becomes available could greatly increase their value in
public health practice.
Understanding disease dynamics is often dependent on mea-
suring disease incidence years or decades in the past, making the
design of suitable data collection particularly challenging. Past inci-
dence rates may  be unmeasured because a disease circulated before
it was  identiﬁed (e.g., HIV before the 1980s), because acute infec-
tion often occurs without identiﬁable symptoms (e.g., dengue, HIV),
or because of poor surveillance. In the latter two  cases, even recent
incidence patterns may  be unknown. Dynamic models can often
be used to infer past incidence with current cross sectional data
or historic samples. Age speciﬁc serologies can be used to esti-
mate the past force of infection, and have been used to measure
historic patterns of the force of infection for dengue and other
diseases (Rodríguez-Barraquer et al., 2013). Phylogenetic models
can be paired with simple epidemic models to infer past epidemic
dynamics, as has been done with HIV and hepatitis C (Stadler et al.,
2012). These techniques, particularly phylogenetic inference, have
become quite popular, but validation has been largely limited to
simulation studies (e.g., Robinson et al., 2013; Volz et al., 2012).
Studies aimed at collecting prospective data speciﬁcally to evalu-
ate serologic and phylogenetic approaches to inferring incidence
would help to place these inferences on ﬁrmer footing.
When responding to emerging epidemics, the problem of miss-
ing data is particularly acute. Here we are forced to forecast the
course of an epidemic with limited knowledge of the pathogen and
burden of disease. Critical data must be collected to carry out this
task, some of which can be measured most effectively early on in
the process of disease emergence. However, this data is not rou-
tinely collected early on, whether due to the difﬁculty of collection,
competing priorities or its value being unrecognized. In particu-
lar, the tendency is to focus almost exclusively on cases early in
an epidemic, whereas those who were at risk but did not become
infected may  carry the most information in terms of population sus-
ceptibility and disease transmissibility. A notable exception is the
2009 H1N1 inﬂuenza pandemic in the United Kingdom, where data
collection was  guided by the long-term involvement of modelers in
the design of control programs. Although not all the data requested
was collected, these efforts enabled policy-relevant modeling dur-
ing the early stages of the epidemic (Ghani et al., 2010; Baguelin
et al., 2010; Eames et al., 2012). This experience illustrates how inte-
gration with the public community can pay off in better inferences
to support policy. At the time of writing, modeling is playing an
important role in the response to the Ebola outbreak in West Africa,
making use of the detailed contact tracing data collected as part
of the response (though for purposes other than modeling) (WHO
Ebola Response Team, 2014). Researchers should challenge them-
selves to identify the most useful classes of models in an emerging
epidemic and the data needed to parameterize them. They should
then work with public health ofﬁcials to integrate collecting this
data into epidemic response plans before such a response is
needed.
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2. Design studies that account for the dynamic nature of
disease systems
Mathematical and computational models are most useful in
understanding disease systems that are dynamic, often containing
structural relationships and feedback loops that lead to behaviors
that are unexpected or do not follow simple functional relation-
ships. Furthermore, these dynamics are often driven by stochastic
processes which are often hard to predict. These factors present
particular challenges for data collection.
While models are extremely useful in understanding disease
systems, they cannot capture every factor that plays a role in driv-
ing disease incidence. Stochasticity and factors outside the modeled
system may  play a primary role in determining whether epidemics
occur and how they develop once underway. Typical examples
include disease introductions, public response to real or perceived
disease threats, and pathogen evolution. It is not always desirable,
or even possible, to model such exogenous factors. However, when
designing studies (or even using existing data) aimed at testing
models, parameterizing models, or assessing the impact of a con-
trol measure, care must be taken in separating the results of factors
lying outside the system from those captured by the model.
The dynamic nature of the disease processes leads to many
practical issues in study design. Accurate sample size calculations
must take into account disease dynamics, and the resulting non-
independence of events. Outside of adjustments for correlation
within clusters (i.e., calculating design effects based on intra-class
correlation coefﬁcients (Kerry and Bland, 1998)), such calculations
are rarely done and may  require complex simulations. The study
itself may  have an effect on the process being studied, and this
effect may  be magniﬁed by dynamic feedback loops in disease sys-
tems. Even “observational” studies may  affect disease dynamics,
as we may  be ethically required to treat the cases of the disease
we detect, and this treatment will affect future incidence (Valle
and Clark, 2013). Finally, interpretation of our observations is con-
tingent on the current state of the system. It is often assumed the
dynamic system is in steady state, but this is rarely the case, and the
phenomena we are most interested in often involve perturbations
to the system that will guarantee that it is not. For instance, the
implications of a particular number of individuals being infected
with a disease for broader disease dynamics depend on whether
data was collected when disease incidence was growing, receding
or in steady state (i.e., the current dynamic regime). Since it is usu-
ally impossible to measure the full state of the system, successful
model driven data collection must not only measure state vari-
ables (e.g., the number susceptible or infectious), but also attempt
to determine the dynamic regime in which those variables were
collected.
Simulation of trial design is a growing area of research, with
numerous applications to vaccine trials (e.g., Van de Velde et al.,
2007; Yang et al., 2006) and growing use in other settings (e.g.,
PopART Cori et al., 2014). The development of standard tools similar
to those available for standard sample size calculations, or even a
list of best practices, would go a long way to expanding the use of
mechanistic models in study design.
3. Identifying critical data collection activities in light of
high dimensional parameter spaces and substantial
structural uncertainty
Infectious disease systems are often the result of a large number
of interacting social and biological processes; hence they can only
be fully characterized by complex models. However, model com-
plexity carries a price, since ﬂexibility makes models difﬁcult to ﬁt
to data or test in a meaningful manner. Simpliﬁcation may  be a path
to creating models that can be ﬁt to data, but may come at the cost
of failing to capture essential system dynamics. High dimensional
models can ﬁt more complex trajectories, but may  have multiple
parameter sets that provide almost indistinguishable ﬁts and can
be almost impossible to test. For models to drive data collection,
modelers face the challenge of identifying the speciﬁc parameters
or predictions of their model that are most essential in increasing
our understanding of the system and testing the structure of the
model itself. Fortunately, mathematical and statistical techniques
exist for identifying what components have the most inﬂuence
on the predictions of complex systems (e.g., Saltelli et al., 1999;
Caswell, 2007). A fruitful avenue may  be to expand these tech-
niques to more directly estimate the value of critical experiments
or studies in reducing our uncertainty about critical outcomes.
Even when the critical study to evaluate or improve a model
has been designed, that study may  be difﬁcult to perform (e.g., out-
comes may  be hard to measure; sample size requirements may be
unreasonably large). When specifying a model reveals these dif-
ﬁculties, the model is serving one of its most important roles in
service of data collection: motivating precision in the statement of
assumptions and hypotheses. For instance, the hypothesis that a
vaccine is “85% effective” at ﬁrst seems simple to test in an obser-
vational study, but once we  attempt to put this into a model the
subtleties of this statement become clear: since vaccination can
change the course of an epidemic the comparison population must
be carefully chosen depending on whether we  seek to measure only
direct protection or both direct and indirect effects; and our inter-
pretation of results may  differ markedly if we believe vaccination
prevents infection completely (as with oral polio vaccine) or only
stops the development of disease (as with injectable polio vaccine).
4. Collecting data to test and parameterize models that
bridge spatial scales
Models of interventions also often rely on assumptions about
how interventions work at an individual level. For example, model-
ing a vaccination intervention involves assumptions about whether
protection is homogeneous or heterogeneous in the population,
how it affects susceptibility to infection compared to the proba-
bility of developing disease given infection, and how it reduces
onward transmission. Each of these differences at the individual
level has important implications for how disease spreads within
populations.
Recent developments in individual- or agent-based simulations
have helped bridge our understanding of the dynamics of infec-
tious disease transmission at different scales, from the individual to
households, schools, towns, cities and countries (Ferguson, 2005;
Eubank et al., 2004). These models have also served as powerful
tools for communicating the insights from models to policy makers.
The best examples in this area are based on well validated sub-
models ﬁt to data on population distributions, human movement,
epidemiological parameters, and within host processes. However,
they are rarely tested against epidemic data at the same spatial scale
(exceptions include Cauchemez et al., 2008). For these approaches
to reach their full potential they require further validation, but how
to do that? Collecting data at the spatial and temporal detail of the
predictions created by these models is unrealistic, and the situa-
tions modeled may  be so unique as to make it impossible to identify
a comparison set. Evaluation of marginal results (i.e., sets of statis-
tics summarizing more detailed model output) is the clear pathway
to validating these models, but work is needed to identify which set
of marginal results need to be tested for a model to be considered
adequately validated for use in forecasting or inference. Innovative
study designs may  help to test key model predictions (e.g., the Flus-
cape study, Read et al., 2014), and there may  be beneﬁt in designing
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models and validating data collection activities in concert to make
validation feasible.
5. Collecting data over time scales commensurate with
model predictions
The predictions from mathematical models often play out over
many years or even decades. Such predictions as increases in herpes
zoster following the introduction of varicella vaccination (Brisson
et al., 2002) or reductions in cervical cancer incidence following
HPV vaccination (Choi et al., 2012) take years to manifest. Like-
wise, proper parameterization and evaluation of dynamic models
often requires decades of data, even for diseases with relatively well
observed outcomes and simple dynamics (e.g., measles, Bjørnstad
et al., 2002). Hence, data collection activities to test model hypothe-
ses or improve model results may  need to take place on timescales
not in line with the usual process of scientiﬁc research or funding.
Focusing on studies that are inexpensive but sustainable may  help
to identify incremental changes to normal surveillance procedures
and sustainable data collection activities that will yield results
over the course of decades. Starting and sustaining such long term
research projects can present a substantial challenge, as they likely
must be sustained outside of normal research funding mechanisms
(which typically fund in increments of 5 years at best). Investiga-
tors may  have to content themselves with helping future scientists,
and public health and scientiﬁc priorities may  have changed by the
time results come in. However, long running cohort studies such
as Multicenter AIDS Cohort Study (Kaslow et al., 1987), Women’s
Health Initiative (Rossouw et al., 2002), the Rakai Health Sciences
Program (Wawer et al., 1999), and the Framingham Heart Study
(Splansky et al., 2007) have shown that long term data collection
activities can yield important, and often unexpected, results. If the
value of these data can be demonstrated to the public health agen-
cies, they can possibly be included in routine surveillance for many
decades to come. Methods that both make incremental use of data
to improve models and provide results as data is collected may  help
to ensure the sustained effort needed to test long term hypotheses.
6. Integrating infectious disease dynamics and modeling
into the every-day scientiﬁc process
Modeling and the study of infectious disease dynamics are
sometimes treated as lying outside the normal scientiﬁc pro-
cess (particularly by those outside of the ﬁeld), being somehow
qualitatively different than laboratory science or other types of
epidemiologic studies. Modelers themselves may  be in part respon-
sible for this perception due to the frequent use of a “parameters
from the literature” approach to building models. However, models
should be an integral part in the ongoing cycle of hypothesis gen-
eration, data collection, and hypothesis reﬁnement (Restif et al.,
2012). A framework for achieving this goal is to build collabora-
tions that closely integrate modeling, ﬁeld studies and laboratory
experiments.
Experimental studies are an area where relationships between
modelers and experimenters have generated questions which can
be addressed directly. For instance, the interplay of mathemati-
cal models and experimental data in animals has contributed to
our understanding of the generation and maintenance of CD8+
T-cell memory (Antia et al., 2005). As an example: a particular
model of homeostasis suggested the total number of CD8+ T-cells
remains stable regardless of exposure to additional pathogens. A
study inducing new long-lived CD8+ T cells in mice was performed
to test this hypothesis. Unexpectedly, the total number of mem-
ory CD8+ T-cells doubled to accommodate the new cells (Vezys
et al., 2009). Thus, a new theory that the number of memory cells
in mammals adapts according to immunological experience was
developed by an iterative discussion between modelers and expe-
rimenters, identifying what data needed to be collected to test a
clearly deﬁned hypothesis.
While numerous instances of such collaborations exist, the per-
ception of the scientiﬁc importance of infectious disease dynamics
is often disconnected from its true importance in disease systems.
Vaccines are an excellent example: licensure is based only on indi-
vidual level effects (though indirect effects may  be estimated);
while public health decisions are heavily inﬂuenced by the indi-
rect effects from vaccination (e.g., herd immunity) and dynamic
components. Integrating cross-disciplinary experiences into the
training of ﬁeld, laboratory, mathematical and computational sci-
entists could help make all more effective and ensure a role for
dynamic models in the scientiﬁc process.
7. Making it common practice to identify data that would
test model hypotheses
The presentation of models and model results should provide
a golden opportunity for identifying those data or studies that
could test the hypotheses underlying the model, reproduce results
or show generalizability. However, few take this opportunity, and
there is a tendency for models to be presented and then forgot-
ten with little or no reﬂection on the quality of the results as more
information becomes available. For models to play an important
role in the progress of science, it is critical to test their qualitative
and quantitative predictions and to reﬁne the underlying models
over time. Perhaps standard practice in the ﬁeld should be to have
a “what studies need to be done” section at the end of each paper
presenting a model or modeling results. As “The Journal on Infec-
tious Disease Dynamics”, Epidemics is well situated to promote such
a practice by encouraging or requiring such a section for research
manuscripts.
Conclusion
These are broad challenges to strengthen the relationship
between models and data collection across experimental, epidemi-
ological and clinical studies of infectious diseases. The breadth of
these challenges provides many opportunities to develop new tech-
niques and standards by applying these concepts to studies in all
areas of infectious disease research. The core principle behind many
of the challenges discussed is that mechanistic models have a role
to play early in the process of experimental and epidemiological
study design, and not only be used for secondary data analysis. The
challenge for the modeler is to identify priorities for what pieces
of information are needed and how to collect them within the con-
ﬁnes of an experimental or epidemiological study. This discussion
will help clarify both the model and study goals, potentially lead-
ing to new “Garki projects” that will drive discovery and innovation
among infectious disease researchers across disciplines.
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